CSBio CSBio

X
[{"orgOrder":0,"company":"Merz Pharma","sponsor":"Winhealth Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Winhealth Pharma and Merz Collaborate on Hepa-Merz\u00ae to benefit patients with liver disease in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Merz Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.

            Lead Product(s): L-Ornithine L-aspartate

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Hepa-Merz

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Winhealth Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 08, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY